AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat 
CoreWeave Q1 2026 Revenue Surges as AI Infrastructure Demand Grows 
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Morgan Stanley Bets on Optical Component Stocks in Greater China Tech Sector 
OCBC Q1 Profit Rises 5% on Strong Wealth Management and Non-Interest Income 
Coinbase Q1 2026 Earnings Miss Sends COIN Stock Lower Amid Crypto Market Slump 
AWS Data Center Overheating Disrupts Cloud Services in Northern Virginia 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
EAST RUTHERFORD, N.J., April 26, 2018 -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that first quarter 2018 financial results will be released on Thursday, May 3, 2018 before the market opens.
The Company will host a conference call to discuss the financial results.
| First Quarter 2018 Earnings Conference Call | |
| When: | Thursday, May 3, 2018 at 8:30 a.m. Eastern Time |
| Dial-in: | 1-877-260-1479 for U.S. |
| 1-334-323-0522 for International | |
| Passcode: 5093025 | |
| Dial-in Replay: | 1-888-203-1112 for U.S. |
| 1-719-457-0820 for International | |
| Passcode: 5093025 | |
| Available through Thursday, May 10, 2018 | |
| Webcast: | www.cambrex.com |
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and continuous processing. For more information, please visit www.cambrex.com.
| Contact: | Stephanie LaFiura |
| Investor Relations Associate | |
| Tel: 201-804-3037 | |
| Email: [email protected] |
